

PROGRESSIVE'S EVENING STROLL

DATE: 15 May, 2025

Market Snapshot:

On the weekly expiry day, the market witnessed significant volatility marked by sharp swings on either sides. Following a subdued opening, Nifty50 initially declined but soon recovered; however, it struggled to sustain the gains and faced another round of selling pressure. Mid-session saw a sudden surge in heavyweight stocks, which pushed the Index beyond the psychological mark of 25,000. By the end of the day, Nifty50 closed the trade at 25,062.10 with gains of 395.20 points. All sectors ended in the green, with Auto and Realty emerging as the top performers. The rally was largely driven by Index-heavyweight stocks, resulting in underperformance from the Midcap and Smallcap segments.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	82530.74	1200.18	1.48
Nifty50	25062.10	395.20	1.60
Nifty Midcap 100	56530.85	394.45	0.70
Nifty Small Cap 100	17239.95	92.50	0.54

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY AUTO	23804.85	448.00	1.92
NIFTY REALTY	897.95	16.95	1.92
NIFTY METAL	9210.05	157.95	1.74
NIFTY MEDIA	1663.05	26.00	1.59

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
HERO MOTOCORP	4325.00	6.34	INDUSIND BANK	780.50	(0.11)
JSW STEEL	1038.30	4.95			
TATA MOTORS	728.10	4.17			
TRENT	5577.50	4.02			

INDICES LEVELS FOR May 16, 2025

Nifty (future)		Bank Nifty (future)	
Resistance	25240	Resistance	55670
Support	24850	Support	55000



PROGRESSIVE'S EVENING STROLL

DATE: 15 May, 2025

KEY TAKEAWAYS OF THE DAY

◆ **HBL gets RDSO approval for Kavach 4.0; Rs37.63bn orders to be delivered in 24 months:**

The company has received an approval from RDSO (first company to receive the approval) for Version 4.0 of Kavach systems. The company can begin deliveries of these systems against its total accumulated order book of Rs37.63bn to be completed within 24 months.

◆ **Shilpa Pharma Lifesciences Unit-1 received USFDA EIR with VAI classification:**

Shilpa Pharma Lifesciences (100% subsidiary of Shilpa) unit-1 has received an EIR from the USFDA and the site is classified as VAI. The inspection was conducted between 3rd-7th March, 2025.

◆ **Infosys completes stake sale in Japan JV HIPUS to Mitsubishi Heavy Industries:**

The company announced the completion of a stake sale in its Japan-based joint venture, HIPUS, to Mitsubishi Heavy Industries (MHI).

◆ **Ireda files bankruptcy against Gensol Engineering:**

Ireda has filed for bankruptcy against Gensol Engineering for defaulting on a Rs5100mn loan. The move follows Sebi's investigation into fund diversion and governance lapses.

◆ **Zydus receives USFDA EIR with No Action Indicated for Ambernath API facility inspection:**

The company has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra. This facility underwent an inspection from 10th-14th February 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).

◆ **Brigade Group acquires 5.4acre land parcel in Chennai for Rs4410mn to develop a housing project:**

The company said the housing project will have a GDV of approximately Rs16,000mn, with a development potential of about 0.8mn sq. ft. The company has acquired a 5.41acre land parcel in Chennai's Velachery Road for Rs4410mn to develop a housing project.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

